Le Lézard
Classified in: Health, Science and technology
Subject: ACC

DSM - Repurchase of shares (7 - 11 October 2019)


HEERLEN, Netherlands, Oct. 15, 2019 /PRNewswire/ -- Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, has repurchased 183,500 of its own shares in the period from 7 October 2019 up to and including 11 October 2019 at an average price of ?107.03. This is in accordance with the repurchase announced on 14 March 2019, covering the intended reduction of issued capital as well as commitments under share-based compensation plans and for stock dividends. The consideration of this repurchase was ?19.6 million.

DSM logo

The total number of shares repurchased under this program to date is 4,812,259 shares for a total consideration of ?508.2 million.

For more detailed information see 'Daily transaction details Share Repurchase Program announced 14 March 2019'.

DSM ? Bright Science. Brighter Living.tm

Royal DSM is a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM's purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders ? customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about ?10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

Or find us on: Facebook, Twitter, LinkedIn, YouTube

Forward-looking statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

For more information:

DSM Media Relations

Lieke de Jong

tel. +31 (0) 45 5782420

e-mail [email protected]

DSM Investor Relations

Dave Huizing

tel. +31 (0) 45 5782864

e-mail [email protected]

PRN NLD


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: